Interní Med. 2018; 20(4): 211-214

Co nového přinesl kongres ESC 2018 o apixabanu?

prof. MUDr. Josef Kautzner, CSc., FESC
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kautzner J. Co nového přinesl kongres ESC 2018 o apixabanu? Interní Med. 2018;20(4):211-214.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace, Europace (2018) 20, 1231-1242. Go to original source... Go to PubMed...
    2. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018 Aug 21; 39(32): 2942-2955. Go to original source... Go to PubMed...
    3. Chen LY, Norby FL, Gottesman RF, et al., Association of Atrial Fibrillation With Cognitive Decline and Dementia Over 20 Years: The ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). J Am Heart Assoc. 2018 Mar 7; 7(6). Go to original source... Go to PubMed...
    4. Alexander C Fanaroff, Jan Steffel, John H Alexander, Gregory Y H Lip, Robert M Califf, Renato D Lopes; Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe, European Heart Journal, Volume 39, Issue 32, 21 August 2018, Pages 2932-2941. Go to original source... Go to PubMed...
    5. Hohnloser SH, Basic E, Hohmann C, Nabauer N. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost. 2018 Mar; 118(3): 526-538. Go to original source... Go to PubMed...
    6. Boriani G, Proietti M, Laroche C, et al., Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018 May 1; 20(5): 747-757. Go to original source... Go to PubMed...
    7. Amin A, Keshishian A, Zhang Q, et al. Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population. Eur Heat J Volume 39, Issue 32, 21 August 2018: 820. Go to original source...
    8. Deitelzweig S, Keshishian A, Li X, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study. Eur Heart J 2018; Volume 39, Issue 32, 21 August 2018: 610. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.